RU2003120446A - Фармацевтическая форма гепирона для перорального введения - Google Patents
Фармацевтическая форма гепирона для перорального введения Download PDFInfo
- Publication number
- RU2003120446A RU2003120446A RU2003120446/15A RU2003120446A RU2003120446A RU 2003120446 A RU2003120446 A RU 2003120446A RU 2003120446/15 A RU2003120446/15 A RU 2003120446/15A RU 2003120446 A RU2003120446 A RU 2003120446A RU 2003120446 A RU2003120446 A RU 2003120446A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical form
- amount
- hepiron
- oral administration
- gepirone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
1. Фармацевтическая форма для перорального введения со свойствами пролонгированного высвобождения, содержащая некоторое количество гидрохлорида гепирона, некоторое количество целлюлозной полимерной матрицы и некоторое количество микрокристаллической целлюлозы, отличающаяся тем, что количество фармацевтически приемлемой целлюлозной полимерной матрицы составляет от 70 до 85 мас.%, количество углеводного связывающего вещества составляет от 7 до 10 мас.% и количество гидрохлорида гепирона составляет от 13 до 21 мас.%.
2. Фармацевтическая форма по п.1, отличающаяся тем, что целлюлозная полимерная матрица является гидроксиметилпропилцеллюлозой, имеющей вязкость от 15000 сантипуаз до 100000 сантипуаз.
3. Фармацевтическая форма по п.1, отличающаяся тем, что микрокристаллической целлюлозой является Avicel pH 101.
4. Лечение депрессии или родственного расстройства центральной нервной системы гепироном, вводимым в пероральной форме для введения один раз в день для пролонгированного высвобождения гепирона, характеризующееся тем, что эта форма определена в п.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00204388.3 | 2000-12-08 | ||
| EP00204388 | 2000-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003120446A true RU2003120446A (ru) | 2005-02-20 |
Family
ID=8172397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003120446/15A RU2003120446A (ru) | 2000-12-08 | 2001-11-30 | Фармацевтическая форма гепирона для перорального введения |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1343504A2 (ru) |
| JP (1) | JP2004517083A (ru) |
| KR (1) | KR20040018314A (ru) |
| CN (1) | CN1479620A (ru) |
| AR (1) | AR031461A1 (ru) |
| AU (1) | AU2002226371A1 (ru) |
| BR (1) | BR0115976A (ru) |
| CA (1) | CA2436692A1 (ru) |
| CZ (1) | CZ20031589A3 (ru) |
| EC (1) | ECSP034627A (ru) |
| HU (1) | HUP0401021A2 (ru) |
| IL (1) | IL155855A0 (ru) |
| MX (1) | MXPA03005099A (ru) |
| NO (1) | NO20032581L (ru) |
| PL (1) | PL362445A1 (ru) |
| RU (1) | RU2003120446A (ru) |
| SK (1) | SK6942003A3 (ru) |
| WO (1) | WO2002045753A2 (ru) |
| ZA (1) | ZA200303915B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545469A1 (en) * | 2002-09-24 | 2005-06-29 | Akzo Nobel N.V. | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| AU2004324868B2 (en) * | 2004-11-05 | 2010-04-29 | Fabre Kramer Holdings Inc | High-dosage extended-release formulation of gepirone |
| MY198454A (en) * | 2017-07-26 | 2023-08-29 | Abbott Lab | Nutritional Tablets and Methods of Making the Same |
| CN109745323A (zh) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | 氮哌酮类化合物提高副交感神经活性的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2001
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/ko not_active Application Discontinuation
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/ru not_active Application Discontinuation
- 2001-11-30 CN CNA018201792A patent/CN1479620A/zh active Pending
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/es unknown
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/ja not_active Withdrawn
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/cs unknown
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/sk unknown
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/hu unknown
- 2001-11-30 IL IL15585501A patent/IL155855A0/xx unknown
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Application Discontinuation
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/pt not_active Application Discontinuation
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 PL PL01362445A patent/PL362445A1/xx not_active Application Discontinuation
- 2001-12-07 AR ARP010105683A patent/AR031461A1/es not_active Application Discontinuation
-
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/es unknown
- 2003-06-06 NO NO20032581A patent/NO20032581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002045753A2 (en) | 2002-06-13 |
| HUP0401021A2 (hu) | 2004-09-28 |
| NO20032581D0 (no) | 2003-06-06 |
| MXPA03005099A (es) | 2004-02-12 |
| ECSP034627A (es) | 2004-09-28 |
| IL155855A0 (en) | 2003-12-23 |
| ZA200303915B (en) | 2004-08-20 |
| CA2436692A1 (en) | 2002-06-13 |
| CN1479620A (zh) | 2004-03-03 |
| KR20040018314A (ko) | 2004-03-03 |
| AU2002226371A1 (en) | 2002-06-18 |
| NO20032581L (no) | 2003-06-06 |
| JP2004517083A (ja) | 2004-06-10 |
| SK6942003A3 (en) | 2003-10-07 |
| BR0115976A (pt) | 2003-12-30 |
| WO2002045753A3 (en) | 2002-08-29 |
| EP1343504A2 (en) | 2003-09-17 |
| PL362445A1 (en) | 2004-11-02 |
| CZ20031589A3 (cs) | 2003-11-12 |
| AR031461A1 (es) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5859060A (en) | Timed release tablet comprising naproxen and pseudoepherine | |
| JP2023041862A5 (ru) | ||
| ES2571703T3 (es) | Formulaciones de oxicodona de una vez al día | |
| JP2003516325A5 (ru) | ||
| FR2752732B1 (fr) | Forme galenique a liberation prolongee de milnacipran | |
| JP2005512995A5 (ru) | ||
| BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
| KR910009254A (ko) | 과식 및/또는 과음후 증상을 치료하기 위한 약제학적 조성물 및 방법 | |
| ATE370727T1 (de) | Pharmazeutische suspensionstabletten- zusammenstellungen | |
| JP2002532392A5 (ru) | ||
| GEP20053501B (en) | Core Tablet for Controlled Release of Gliclazide after Oral Administration | |
| BRPI0713306A2 (pt) | composição farmacêutica compreendendo amlodipina e losartan | |
| CA2157323A1 (en) | Gepirone dosage form | |
| EA200001201A2 (ru) | Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем | |
| EP0375628A3 (en) | Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment | |
| US4657757A (en) | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| RU2003120446A (ru) | Фармацевтическая форма гепирона для перорального введения | |
| RU2002129873A (ru) | Применение олтипраза для профилактики и лечения фиброза и цирроза печени и фармацевтическая композиция, содержащая олтипраз | |
| RU2005105302A (ru) | Композиция бицифадина | |
| CA2248968C (en) | Nasal administration of agents for treatment of delayed onset emesis | |
| RU98105506A (ru) | Оральное применение (+)-о-деметилтрамадола в качестве анальгетика | |
| CA2341485A1 (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
| CA2345521A1 (en) | Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration | |
| TW492879B (en) | Lutidine compounds matrix type controlled drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |